Published online before print December 29, 2003, doi: 10.1161/01.RES.0000115557.25127.8D
© 2004 American Heart Association, Inc.
Integrative Physiology |
Interleukin-6 Induces Oxidative Stress and Endothelial Dysfunction by Overexpression of the Angiotensin II Type 1 Receptor
From the Medizinische Klinik und Poliklinik (S.W., M.S., K.S., M.B., G.N.), Innere Medizin III, and Physiologisches Institut (A.S.), Universitätskliniken des Saarlandes, Homburg/Saar, Germany; and Department of Cardiology and Angiology (B.S.), Medizinische Hochschule Hannover, Hannover, Germany.
Correspondence to Dr Sven Wassmann, Medizinische Klinik und Poliklinik, Innere Medizin III, Universitätskliniken des Saarlandes, D-66421 Homburg/Saar, Germany. E-mail wassmann{at}med-in.uni-saarland.de
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Angiotensin II type 1 (AT1) receptor activation as well as proinflammatory cytokines such as interleukin-6 (IL-6) are involved in the development and progression of atherosclerosis. The detailed underlying mechanisms including interactions between inflammatory agonists and the renin-angiotensin system are poorly understood. Stimulation of cultured rat aortic vascular smooth muscle cells (VSMCs) with IL-6 led to upregulation of AT1 receptor mRNA and protein expression, as assessed by Northern and Western blot experiments. Nuclear run-on and transcription blockade experiments showed that IL-6 increases AT1 receptor mRNA de novo synthesis but not mRNA stability. Preincubation of VSMCs with IL-6 resulted in an enhanced angiotensin II–induced production of reactive oxygen species, as assessed by DCF fluorescence laser microscopy. Treatment of C57BL/6J mice with IL-6 for 18 days increased vascular AT1 receptor expression (real-time RT-PCR) and angiotensin II–induced vasoconstriction, enhanced vascular superoxide production (L-012 chemiluminescence, DHE fluorescence), and impaired endothelium-dependent vasodilatation. These effects were completely omitted in AT1 receptor knockout mice (AT1A-/- mice). Upregulation of vascular AT1 receptor expression in vitro and in vivo is decisively involved in IL-6–induced propagation of oxidative stress and endothelial dysfunction. This interaction of the proinflammatory cytokine IL-6 with the renin-angiotensin system may represent an important pathogenetic mechanism in the atherosclerotic process.
Key Words: endothelial dysfunction • AT1 receptor • interleukin-6 • inflammation • oxidative stress
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Basic science as well as clinical studies have recently demonstrated that inflammatory events play an important role at virtually all stages of atherosclerosis.1,2 Exposure to risk factors such as hyperlipidemia or smoking triggers early vascular inflammation, which includes recruitment of leukocytes to the diseased endothelium, penetration of these inflammatory cells into the vessel wall, and initiation of atherosclerotic lesions.1–3 This so-called endothelial dysfunction resembles not only an early state of atherosclerosis but also predicts a high cardiovascular event rate.4–7 Ultimately, rupture of atherosclerotic lesions marks the event of acute coronary syndromes associated with high morbidity and mortality rates.1,2 Inflammatory events decisively contribute to the underlying destabilization of these vulnerable plaques.1,2
Cellular events such as adhesion, migration, and invasion of leukocytes into vascular cells occur concomitantly with the production of proinflammatory cytokines such as interleukin-6 (IL-6), which are thought to play a major role in the pathogenesis of atherosclerosis.8,9 Besides their potential role in local vascular disease progression, the circulating concentrations of these cytokines serve as markers for adverse prognosis.10
On the other hand, the renin-angiotensin system (RAS) and especially activation of the angiotensin II type 1 (AT1) receptor participates in all stages of atherosclerosis.11,12 This is particularly evident for endothelial dysfunction and plaque destabilization, which is in part explained by the induction of oxidative stress by AT1 receptor overexpression and activation.11,12 In addition, angiotensin II is known to increase the production of proinflammatory cytokines such as IL-6.13–16 However, the detailed mechanisms underlying the interaction of the RAS and inflammatory events remain poorly understood.
We reasoned that IL-6 could possibly influence the RAS on the level of AT1 receptor expression, which could in turn be important for the development of vascular dysfunction. Therefore, we examined the effect of IL-6 on AT1 receptor expression in vitro and in vivo and the potential relevance for the onset of endothelial dysfunction.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Materials
Recombinant mouse IL-6 was obtained from Calbiochem (Bad Soden, Germany). Angiotensin II, 5,6-dichlorobenzimidazole, Taq DNA polymerase, nucleotides, salts, and other chemicals were purchased from Sigma Chemical. MMLV reverse transcriptase, antibiotics, calf serum, and cell culture medium were obtained from Invitrogen. SYBR Green PCR master mix was purchased from Applied Biosystems. H2DCF-DA was obtained from Molecular Probes. [32P]-dCTP and Hybond N-nylon membranes were purchased from Amersham. RNA-clean was obtained from AGS. L-012 was kindly provided by Dr Sohn, Institute of Physiology, Ludwig Maximilians University, Munich, Germany.
Cell Culture
Vascular smooth muscle cells (VSMCs) were isolated from rat thoracic aorta and cultured over several passages, as described previously.17 Experiments were performed with cells from passage 5 to 10.
Animals
Male 12-week-old wild-type C57BL/6J mice (WT; Charles River, Sulzfeld, Germany) and male, age-matched AT1 receptor knockout mice (AT1A-/-) with the identical genetic background (C57BL/6J; kindly provided by Dr Coffman, Department of Medicine, University of North Carolina, Chapel Hill, NC) were used for this study.18 The knockout animals were additionally backcrossed five times with C57BL/6J mice, which were used as control animals. Genotypes were determined by polymerase chain reaction (PCR) amplification of tail DNA. Animals were maintained in a 22°C room with a 12-hour light/dark cycle and received standard chow and drinking water ad libitum. The mice were treated for 18 days twice daily with increasing doses of recombinant mouse IL-6 (40 ng/day, days 1 to 4; 80 ng/day, days 5 to 12; 160 ng/day; days 13 to 18) or vehicle intraperitoneally according to the protocol of Wallenius et al.19 In the latter study, intraperitoneal injection of 80 ng IL-6 led to a 2-fold increase of IL-6 serum levels. These serum levels were about 10- to 20-fold lower than after endotoxin challenge.19 Body weights were similar in both mice groups (WT, 22.2±0.6 grams; AT1A-/-, 21.0±0.5 grams) and were not significantly altered by IL-6 treatment (WT, 22.8±0.4 grams; AT1A-/-, 21.5±0.4 grams). Food intake and behavior of the animals were not influenced by IL-6 treatment. The mice were killed after the treatment period and tissue samples were collected immediately. There were no signs of peritonitis. Animal experiments were performed in accordance with the German animal protection law.
mRNA Isolation and Northern Blot Analysis
Cells were treated as indicated. IL-6 treatment did not affect cellular viability of the cultured cells, as determined by cell count, morphology, and trypan blue exclusion. Total cellular RNA was isolated with RNA-clean according to the manufacturer’s protocol. Then, 10 µg aliquots were electrophoresed and Northern analysis was performed with a [32P]-dCTP-labeled, rat AT1 receptor cDNA probe, as described previously.17 Blots were exposed to film, and autoradiographic signals were quantified by laser densitometry. The AT1 receptor mRNA expression levels were normalized to the corresponding RNA loading.
Real-Time Polymerase Chain Reaction
For assessment of vascular gene expression, mouse aortas were excised, quickly frozen in liquid nitrogen, and homogenized with a motorized homogenizer. RNA from aortic homogenates was isolated with RNA-clean, and 1-µg aliquots were electrophoresed as described above. Then, 1 µg of the isolated total RNA was reverse transcribed using random primers and MMLV reverse transcriptase for 60 minutes at 42°C and 10 minutes at 75°C. The single-stranded cDNA was amplified by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) with the TaqMan system (ABI-Prism 7700 Sequence Detection System, Applied Biosystems) using SYBR Green dye. For AT1 receptor, the primers were 5'-GGGTGGACAATGGCCAGGTAG-3' and 5'-CTCGCCCTGG- CTGACTTATGC-3' (murine AT1A receptor). For GAPDH, the primers were 5'-CCTGGACCACCCAGCCAGCAA-3' and 5'-TGTTATGGGGTCTGGGATA-3'. For quantification, AT1 receptor mRNA expression was normalized to the expressed housekeeping gene GAPDH.
Nuclear Run-On Assays
VSMCs were treated as indicated, collected, and washed. After lysis for 10 minutes on ice, nuclei were isolated by centrifugation through 0.6 mol/L sucrose, as described previously.17 The nuclei (
3 to 5x108/reaction) were used to carry out the in vitro transcription in a reaction mixture containing 40% glycerol, 50 mmol/L Tris/HCl, 5 mmol/L MgCl2, 0.1 mmol/L EDTA, 0.5 mmol/L levels of CTP, GTP, ATP, and UTP at 30°C for 30 minutes. Reactions were terminated by addition of RNA-clean. Immediately before transcription, a sample of each condition was removed. Total RNA before and after transcription was isolated, and AT1 receptor and GAPDH mRNA were quantified by real-time RT-PCR, as described above. The extent of AT1 receptor mRNA transcription was determined by subtracting the amount of AT1 receptor mRNA standardized to GAPDH mRNA before transcription from the amounts after transcription.
Western Blotting
After treatment, VSMCs were homogenized in ice-cold lysis buffer containing additional leupeptin and aprotinin. Membrane proteins were isolated, and 30 µg-aliquots were separated on SDS/PAGE, as described previously.20 Blot membranes were stained with Ponceau red to verify appropriate protein transfer and equal loading for each lane. Immunoblotting was performed with an AT1 receptor rabbit polyclonal IgG antibody (1:250 dilution, sc 1173, AT1 (N-10), Santa Cruz Biotechnology). Immunodetection was accomplished using a goat anti-rabbit secondary antibody (1:5000 dilution, Sigma Chemical) and the enhanced chemiluminescence kit (Amersham).
Measurement of Reactive Oxygen Species
Intracellular production of reactive oxygen species in VSMCs was measured by 2',7'-dichlorofluorescein (DCF; 10 µmol/L) fluorescence using confocal laser-scanning microscopy techniques (Zeiss Axiovert 135 microscope, Bio-Rad MRC-600 confocal attachment, laser excitation 488 nm, emission longpass LP515-nm filter set) as described previously.17 Images were collected by single rapid scans and identical parameters, such as contrast and brightness, for all samples. Five groups of 25 cells for each sample were randomly selected from the image, and fluorescent intensity was taken. The relative fluorescence intensities are average values of all experiments.
Superoxide release in intact aortic segments was determined by L-012 chemiluminescence according to Sohn et al.21 L-012 is a luminol derivate with a high sensitivity for reactive oxygen species, which does not exert redox cycling itself.21 Aortas were carefully excised and placed in chilled, modified Krebs-HEPES buffer (pH 7.4; in mmol/L: NaCl 99.01, KCl 4.69, CaCl2 1.87, MgSO4 1.20, NaHEPES 20.0, K2HPO4 1.03, NaHCO3 25.0, and D(+)Glucose 11.1). Connective tissue was removed, and aortas were cut into 3-mm segments. The aortic segments were transferred into scintillation vials containing Krebs-HEPES buffer with 100 µmol/L L-012 and were incubated for 5 minutes. Chemiluminescence was then assessed over 15 minutes in a scintillation counter (Lumat LB 9501, Berthold) in 1-minute intervals. The vessel segments were then dried, and dry weight was determined. Superoxide release is expressed as relative chemiluminescence per milligram of aortic tissue.
To assess vascular superoxide production by a second approach, dihydroethidium (DHE) fluorescence of aortic tissue sections was used. Aortas were prepared as described above and 4-mm segments were embedded in Tissue Tek OCT embedding medium (Miles Laboratories), snap-frozen, and stored at -80°C. Samples were sectioned on a Leica cryostat (20 µm) and placed on glass slides. Krebs-HEPES buffer containing 2 µmol/L DHE was topically applied to each tissue section and sections were incubated in a dark, humidified chamber at 37°C for 30 minutes. In situ production of superoxide was visualized as fluorescence by confocal laser-scanning microscopy, as described above (laser excitation 514 nm, emission longpass LP550-nm filter). Paired aortas from vehicle-treated and IL-6–treated animals were processed in parallel, and images were acquired with identical acquisition parameters and were stored digitally.
Aortic Ring Preparations and Tension Recording
After excision of the descending aorta, the vessel was immersed in chilled buffer containing (in mmol/L) NaCl 118.0, CaCl2 2.5, KCl 4.73, MgCl2 1.2, KH2PO4 1.2, NaHCO3 25.0, NaEDTA 0.026, and D(+)Glucose 5.5; pH 7.4. Adventitial tissue was carefully removed. Three-millimeter rings were mounted in organ baths filled with the described buffer (37°C; continuously aerated with 95% O2 and 5% CO2), were attached to a force transducer, and isometric tension was recorded. The vessel segments were gradually stretched over 60 minutes to a resting tension of 10 mN (1 gram), which was maintained throughout the experiment, and were allowed to equilibrate for further 30 minutes. Drugs were added in increasing concentrations in order to obtain cumulative concentration-response curves: KCl 20 and 40 mmol/L, angiotensin II 1 nmol/L to 1 µmol/L, phenylephrine 1 nmol/L to 10 µmol/L, carbachol 10 nmol/L to 100 µmol/L, and nitroglycerin 1 nmol/L to 10 µmol/L. The drug concentration was increased when vasoconstriction or relaxation was completed. Drugs were washed out before the next substance was added.
Statistical Analysis
Data are presented as mean±SEM obtained in at least three separate experiments. Statistical analysis was performed using the ANOVA test. A value of P<0.05 indicates statistical significance.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
IL-6 Upregulates AT1 Receptor Gene Expression in VSMCs
VSMCs were incubated for 0, 2, 4, 12, and 24 hours with 1 nmol/L IL-6 or vehicle, followed by quantification of AT1 receptor mRNA expression by Northern analysis. Figures 1A and 1B show a representative autoradiogram and the densitometric analysis of four separate experiments and reveal a time-dependent upregulation of AT1 receptor mRNA expression to a maximum of 166±25% of control after 12 hours (P<0.05 versus control). The IL-6 effect was already detected at a concentration of 0.1 nmol/L (139±15% of control; P<0.05 versus control; n=3), as demonstrated in Figure 1C.
|
AT1 receptor protein expression was assessed by Western blotting in VSMCs stimulated for 24 hours with 1 nmol/L IL-6 or vehicle. Figures 2A and 2B show that IL-6 also induced an enhanced AT1 receptor expression on protein level (165±20% of control; P<0.05 versus control; n=6). Expression of ß-actin, which was used as internal control, was not altered by IL-6 (115±24% of control).
|
IL-6 Increases AT1 Receptor mRNA Transcription Rate
To explore the gene regulation mechanisms, VSMCs were incubated for 12 hours with 1 nmol/L IL-6 or vehicle, before nuclear mRNA de novo synthesis was assessed by nuclear run-on assays. Figure 3A demonstrates that IL-6 induced an increase of AT1 receptor mRNA transcription rate to 129±3% of control (P<0.05 versus control; n=3). GAPDH mRNA expression was not significantly altered (data not shown).
|
In addition, mRNA stability was assessed in VSMCs stimulated for 12 hours with 1 nmol/L IL-6 or vehicle, followed by transcriptional blockade with 50 µg/mL of the RNA polymerase II inhibitor 5,6-dichlorobenzimidazole (DRB), which blocks de novo synthesis of mRNA.22 Figure 3B shows the quantification of AT1 receptor mRNA decay and reveals that IL-6 had no influence on AT1 receptor mRNA stability (n=4).
IL-6–Induced AT1 Receptor Overexpression Enhances Reactive Oxygen Species Production in VSMCs
VSMCs were preincubated for 24 hours with 1 nmol/L IL-6 or vehicle, before 1 µmol/L angiotensin II was added for an additional 3 hours. Production of reactive oxygen species was assessed by DCF fluorescence confocal laser microscopy. Figures 4A and 4B depict a representative microscopic scan and the data analysis of four separate experiments. Preincubation with IL-6 significantly increased angiotensin II–mediated free radical production in VSMCs (angiotensin II, 181±14% of control; IL-6+angiotensin II, 225±14% of control; P<0.05 versus control and versus angiotensin II alone, n=4). IL-6 had no significant effect on basal production of reactive oxygen species (114±9% of control).
|
IL-6 Enhances Vascular AT1 Receptor Expression and Oxidative Stress In Vivo
Male wild-type C57BL/6J mice were treated intraperitoneally with increasing doses of murine IL-6 or vehicle for 18 days (40 ng/day, days 1 to 4; 80 ng/day, days 5 to 12; 160 ng/day; days 13 to 18). Aortas were excised after treatment and AT1 receptor mRNA expression was measured by real-time quantitative RT-PCR. Figure 5A shows that IL-6 treatment enhanced vascular AT1 receptor mRNA expression to 163±35% of the control animals (P<0.05 versus control; n=5 per group). GAPDH mRNA expression was not significantly altered (data not shown).
|
Concomitantly, superoxide production in aortic segments was enhanced after treatment with IL-6, as assessed by DHE fluorescence of aortic tissue sections (n=4 per group) (Figure 5B). This increase in superoxide production was confirmed by L-012 chemiluminescence (163±32% of control; P<0.05 versus control; n=6 per group), as shown in Figure 5C.
In addition, vascular function of isolated, intact aortic ring preparations was assessed in organ chamber experiments (n=4 with 10 rings per group). Treatment with IL-6 induced a marked impairment of endothelium-dependent vasodilatation, as assessed by stimulation with carbachol (P<0.05 versus control group; 10 and 100 µmol/L carbachol) (Figure 6A). In contrast, endothelium-independent vasorelaxation induced by nitroglycerin was not altered (Figure 6B). Moreover, angiotensin II–induced vasoconstriction was significantly enhanced after IL-6 treatment compared with vehicle-treated mice (P<0.05 versus control group; 1 µmol/L angiotensin II), whereas vasoconstriction induced by phenylephrine or KCl was not affected by IL-6 treatment (data not shown).
|
IL-6–Induced Oxidative Stress and Endothelial Dysfunction Are Omitted in AT1 Receptor Knockout Mice
Mice lacking the AT1A receptor (AT1A-/- mice) with the same genetic background as the wild-type animals were treated with IL-6 or vehicle for 18 days identical to the wild-type group, and oxidative stress (n=4 to 7 per group) and functional performance of aortic ring preparations (n=4 with 10 rings per group) were assessed as described above. Figures 7A and 7B demonstrate that in contrast to wild-type animals, treatment with IL-6 did not significantly enhance vascular superoxide production in AT1A-/- mice (119±16% of vehicle-treated AT1A-/- mice, L-012 chemiluminescence). Accordingly, endothelium-dependent vasorelaxation was not significantly different after IL-6 treatment compared with vehicle-treated AT1A-/- mice (Figure 7C). As expected, angiotensin II–induced vasoconstriction was almost absent in AT1A-/- mice and was not affected by IL-6 (data not shown). Finally, phenylephrine-induced vasocontraction and nitroglycerin-mediated vasorelaxation were not altered by IL-6 treatment in the AT1A-/- mice (data not shown).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The data of the presented study demonstrate that the proinflammatory cytokine IL-6 induces an upregulation of AT1 receptor gene expression in cultured VSMCs and in vascular tissue of mice. In consequence, this leads to increased angiotensin II–mediated vasoconstriction, enhanced free oxygen radical production in vitro and in vivo, and to the development of endothelial dysfunction. It is well established that oxidative stress plays a major role in the pathogenesis of endothelial dysfunction and that AT1 receptor activation leads to an increased production of reactive oxygen species in vascular cells.11,23–25 The reduction of oxidative stress by antioxidants or genetic disruption of reactive oxygen species–producing enzymes was shown to be associated with an improvement of endothelial function.11,24–26
IL-6 increases AT1 receptor expression by enhancement of the mRNA transcription rate, whereas alteration of mRNA stability is not the underlying gene regulatory mechanism. It is known that AT1 receptor expression is influenced by many agonists, such as angiotensin II, LDL cholesterol, hormones such as estrogen, progesterone and insulin, and growth factors.27–32 Numerous experimental studies have confirmed this regulative pathway which leads to either reduced effects of AT1 receptor activation (eg, angiotensin II, estrogen, growth factors) or to an enhancement of AT1 receptor–mediated effects (eg, progesterone, LDL cholesterol, insulin).27–32 Frequently, this is caused by alteration of AT1 receptor mRNA stability, but changes in AT1 receptor mRNA transcription rate have also been described, as for example for angiotensin II and progesterone, involving numerous signal transduction pathways, such as cytosolic calcium, MAP kinases, and nitric oxide.11,12
Proinflammatory cytokines such as IL-6 have been implicated in the pathogenesis of atherosclerosis.1,2 This assumption is mainly based on two pieces of evidence. On one hand, experimental data suggest that cytokines are important for the recruitment, adhesion, invasion, and functioning of leukocytes within the diseased vessel wall through propagated migration, proliferation, activity, and phagocytosis of leukocytes.1,2 In a murine model of atherosclerosis, IL-6 was shown to increase atherosclerotic lesion size.33 On the other hand, circulating levels of cytokines such as IL-6 have been shown to correlate with an adverse prognosis of patients suffering from coronary artery disease.1,10 However, the detailed mechanisms of how cytokines may accelerate the development of atherosclerosis remain poorly understood. Finding these mechanisms could be essential to establish antiatherosclerotic treatment strategies depending on circulating levels of IL-6.
The presented data demonstrate that IL-6 upregulates vascular AT1 receptor expression. This is of potential importance for the following reasons. First, IL-6 has been detected within stable and unstable plaques together with components of the RAS such as the AT1 receptor.14 Activation of the latter enhances IL-6 production which suggests important interactions between IL-6 and the AT1 receptor.13–16 Second, a great body of evidence derived from experimental studies indicates the decisive involvement of AT1 receptor activation in the development and progression of endothelial dysfunction and atherosclerosis.11,12,34 Interventional trials have revealed that prevention of AT1 receptor activation by ACE inhibition or AT1 receptor antagonism may inhibit onset and progression of endothelial dysfunction, atherosclerosis and related organ damage.35–40
AT1 receptor expression seems to be limiting for the effect of angiotensin II. Upregulation of AT1 receptor expression by, for example, LDL cholesterol enhances the action of angiotensin II in vitro as well as in vivo. AT1 receptors are downregulated by growth factors, estrogen, and angiotensin II, which diminishes the effects of angiotensin II on intracellular signaling.27–32 In the present study, upregulation of AT1 receptor expression by IL-6 in VSMCs was associated with an increased angiotensin II–mediated production of reactive oxygen species, indicating that the AT1 receptor overexpression led to an enhancement of AT1 receptor–mediated effects and to increased oxidative stress in VSMCs. Angiotensin II is abundantly circulating in the blood of mice and locally expressed in vascular cells and evokes more pronounced effects in the case of enhanced vascular AT1 receptor expression. Therefore, the increase in oxidative stress in association with AT1 receptor upregulation after treatment with IL-6 is in good agreement with the in vitro data and confirms the relevance of these data in vivo. Moreover, the effect on vascular oxidative stress in the absence of exogenously administered angiotensin II underlines the pathophysiological relevance of the presented findings, because it occurs without a pharmacologically induced increase of angiotensin II concentrations.
In the present study, IL-6 concentrations were chosen for the cell culture experiments that were used in other in vitro studies as well.41 However, these concentrations exceed the plasma levels found in humans. Mice display 10- to 20-fold higher IL-6 plasma levels than humans.19 Importantly, the treatment of mice with IL-6 according to the protocol that was used in the present study leads to a 2-fold increase in IL-6 plasma concentrations.19 In human studies, different basal IL-6 levels were detected; however, in patients with acute coronary syndromes, a 2-fold increase in IL-6 concentrations was found.42,43 Therefore, the findings of the presented in vivo study may be relevant for the in vivo situation in humans.
By upregulating vascular AT1 receptor expression, the harmful effects of AT1 receptor activation are enhanced by IL-6. Overexpression of AT1 receptors leads to increased oxidative stress in vitro and in vivo, which in turn causes the development of endothelial dysfunction, the prerequisite of atherosclerosis, which is associated with a poor prognosis.4–7,11,23 It could be argued that the diverse effects of IL-6 may cause a variety of harmful events, ultimately leading to vascular damage. However, the presented data derived from AT1A-/- mice strongly suggest that the demonstrated AT1 receptor upregulation is a major event leading to the adverse vascular effects of IL-6. Thus, the herein presented data combined with previous findings could be summarized in a proinflammatory vicious circle: AT1 receptor activation by angiotensin II increases the production of IL-6,13–16 which in turn enhances AT1 receptor expression, leading to increased vasoconstriction, enhanced oxidative stress, inflammatory events, endothelial dysfunction, and possibly to the subsequent development of vascular lesions.
If confirmed in humans, these results could be of potential importance for antiatherosclerotic treatment strategies. It may be speculated that elevated IL-6 plasma concentrations mark patients with an activated RAS and increased expression of AT1 receptors. This could not only predict a poor prognosis but could putatively identify patients who especially benefit from a medical treatment that diminishes AT1 receptor activation.
|
Acknowledgments |
|---|
This study was supported by the Deutsche Forschungsgemeinschaft. The excellent technical assistance of Sybille Richter is greatly appreciated.
|
Footnotes |
|---|
Original received September 26, 2003; revision received November 20, 2003; accepted December 5, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135–1143.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.
3. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002; 22: 1257–1266.
4. Vita JA, Keaney JF. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002; 106: 640–642.
5. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948–954.
6. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101: 1899–1906.
7. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002; 106: 653–658.
8. Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T, Tsuruya Y, Kano S. Interleukin-6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol. 1991; 260: H1713–H1717.[Medline] [Order article via Infotrieve]
9. Boring L, Gosling J, Cleary M, Charo EF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 294: 894–897.
10. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767–1772.
11. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part I: oxidative stress and atherogenesis. Circulation. 2002; 105: 393–396.
12. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part II: AT1 receptor regulation. Circulation. 2002; 105: 530–536.
13. Han Y, Runge MS, Brasier AR. Angiotensin II induces IL-6 transcription in vascular smooth muscle cells through pleiotropic activation of NF-
B transcription factors. Circ Res. 1999; 84: 695–703.
14. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372–1378.
15. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II–induced JAK/STAT signaling and cytokine induction. Circ Res. 2000; 87: 1195–1201.
16. Funakoshi Y, Ichiki T, Ito K, Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension. 1999; 34: 118–125.
17. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and rac1 GTPase. Mol Pharmacol. 2001; 59: 646–654.
18. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci U S A. 1995; 92: 3521–3525.
19. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6–deficient mice develop mature-onset obesity. Nat Med. 2002; 8: 75–79.[CrossRef][Medline] [Order article via Infotrieve]
20. Wassmann S, Laufs U, Bäumer AT, Müller K, Ahlbory K, Linz W, Itter G, Rösen R, Böhm M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001; 37: 1450–1457.
21. Sohn HY, Gloe T, Keller M, Schoenafinger K, Pohl U. Sensitive superoxide detection in vascular cells by the new chemiluminescence dye L-012. J Vasc Res. 1999; 36: 456–464.[CrossRef][Medline] [Order article via Infotrieve]
22. Hensold JO, Barth D, Stratton CA. RNA polymerase II inhibitor, 5,6-dichloro-1-ß-D-ribofuranosylbenzimidazole (DRB), causes erythroleukemic differentiation and transcriptional activation of erythroid genes. J Cell Physiol. 1996; 168: 105–113.[CrossRef][Medline] [Order article via Infotrieve]
23. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001; 104: 2673–2678.
24. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000; 87: 840–844.
25. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction: modulation by statins. Endothelium. 2003; 10: 23–33.[CrossRef][Medline] [Order article via Infotrieve]
26. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction mice. Circ Res. 2002; 91: 173–179.
27. Nickenig G, Röling J, Strehlow K, Schnabel P, Böhm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation. 1998; 98: 2453–2460.
28. Lassegue B, Alexander RW, Nickenig G, Clark M, Murphy TJ, Griendling KK. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and posttranscriptional mechanisms: evidence for homologous and heterologous regulation. Mol Pharmacol. 1995; 48: 601–609.[Abstract]
29. Nickenig G, Bäumer AT, Grohé C, Kahlert S, Strehlow K, Rosenkranz S, Stäblein A, Beckers F, Smits JFM, Daemen MJAP, Vetter H, Böhm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998; 97: 2197–2201.
30. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low density lipoprotein in vascular smooth muscle cells. Circulation. 1997; 95: 473–478.
31. Nickenig G, Strehlow K, Wassmann S, Bäumer AT, Ahlbory K, Sauer H, Böhm M. Differential effects of estrogen and progesterone on AT1 receptor gene expression in vascular smooth muscle cells. Circulation. 2000; 102: 1828–1833.
32. Nickenig G, Murphy TJ. Down-regulation by growth factors of vascular smooth muscle angiotensin receptor gene expression. Mol Pharmacol. 1994; 46: 653–659.[Abstract]
33. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999; 19: 2364–2367.
34. Strawn WB, Chapell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000; 101: 1586–1593.
35. Mancini GB, Henry GC, Macaya C, O’Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin converting enzyme inhibition with quinapril improves endothelial dysfunction in patients with coronary artery disease. Circulation. 1996; 94: 258–265.
36. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, Ellahham S, Quyyumi AA. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation. 2000; 101: 2349–2354.
37. Schiffrin EL, Park JB, Intengan HD, Touyz R. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000; 101: 1653–1659.
38. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342: 821–828.[Medline] [Order article via Infotrieve]
39. Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme, ramipril, on cardiovascular events. N Engl J Med. 2000; 342: 145–153.
40. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med. 1987; 316: 1429–1435.[Abstract]
41. Ohkawa F, Ikeda U, Kanbe T, Kawasaki K, Shimada K. Effects of inflammatory cytokines on vascular tone. Cardiovasc Res. 1995; 30: 711–715.[CrossRef][Medline] [Order article via Infotrieve]
42. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG, Crea F, Pepys MB, Maseri A. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998; 98: 2370–2376.
43. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996; 94: 874–877.
This article has been cited by other articles:
 |
|
 |
|
  B. Ponnuchamy and R. A. Khalil Cellular mediators of renal vascular dysfunction in hypertension Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1001 - R1018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-F. Lam, P.-J. Chang, Y.-S. Huang, Y.-H. Sung, C.-C. Huang, M.-W. Lin, Y.-C. Liu, and Y.-C. Tsai Prolonged Use of High-Dose Morphine Impairs Angiogenesis and Mobilization of Endothelial Progenitor Cells in Mice Anesth. Analg., August 1, 2008; 107(2): 686 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Satou, R. A. Gonzalez-Villalobos, K. Miyata, N. Ohashi, A. Katsurada, L. G. Navar, and H. Kobori Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells Am J Physiol Renal Physiol, July 1, 2008; 295(1): F283 - F289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Martinez-Revelles, F. Jimenez-Altayo, L. Caracuel, F. J. Perez-Asensio, A. M. Planas, and E. Vila Endothelial Dysfunction in Rat Mesenteric Resistance Artery after Transient Middle Cerebral Artery Occlusion J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 363 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chrissobolis, S. P. Didion, D. A. Kinzenbaw, L. I. Schrader, S. Dayal, S. R. Lentz, and F. M. Faraci Glutathione Peroxidase-1 Plays a Major Role in Protecting Against Angiotensin II-Induced Vascular Dysfunction Hypertension, April 1, 2008; 51(4): 872 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Schrader, D. A. Kinzenbaw, A. W. Johnson, F. M. Faraci, and S. P. Didion IL-6 Deficiency Protects Against Angiotensin II Induced Endothelial Dysfunction and Hypertrophy Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2576 - 2581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Muller, N. Schweitzer, O. Johren, P. Dominiak, and W. Raasch Angiotensin II stimulates the reactivity of the pituitary-adrenal axis in leptin-resistant Zucker rats, thereby influencing the glucose utilization Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E802 - E810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. I. Boesen and D. M. Pollock Effect of chronic IL-6 infusion on acute pressor responses to vasoconstrictors in mice Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1745 - H1749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Haurani and P. J. Pagano Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: Bellwether for vascular disease? Cardiovasc Res, September 1, 2007; 75(4): 679 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Zemse, R. H. P. Hilgers, and R. C. Webb Interleukin-10 counteracts impaired endothelium-dependent relaxation induced by ANG II in murine aortic rings Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3103 - H3108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Wahba and R. H. Mak Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 550 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Elton and M. M. Martin Angiotensin II Type 1 Receptor Gene Regulation: Transcriptional and Posttranscriptional Mechanisms Hypertension, May 1, 2007; 49(5): 953 - 961. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kurihara, Y. Ozawa, K. Shinoda, N. Nagai, M. Inoue, Y. Oike, K. Tsubota, S. Ishida, and H. Okano Neuroprotective Effects of Angiotensin II Type 1 Receptor (AT1R) Blocker, Telmisartan, via Modulating AT1R and AT2R Signaling in Retinal Inflammation Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5545 - 5552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wassmann, N. Werner, T. Czech, and G. Nickenig Improvement of Endothelial Function by Systemic Transfusion of Vascular Progenitor Cells Circ. Res., October 13, 2006; 99(8): E74 - E83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cheng, W. Cao, J. Behar, C. Fiocchi, P. Biancani, and K. M. Harnett Acid-Induced Release of Platelet-Activating Factor by Human Esophageal Mucosa Induces Inflammatory Mediators in Circular Smooth Muscle J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 117 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cheng, W. Cao, C. Fiocchi, J. Behar, P. Biancani, and K. M. Harnett HCl-induced inflammatory mediators in cat esophageal mucosa and inflammatory mediators in esophageal circular muscle in an in vitro model of esophagitis Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1307 - G1317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Lee, L. C. Sturgis, H. Labazi, J. B. Osborne Jr., C. Fleming, J. S. Pollock, M. Manhiani, J. D. Imig, and M. W. Brands Angiotensin II hypertension is attenuated in interleukin-6 knockout mice Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H935 - H940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Matsuno, H. Yamada, K. Iwata, D. Jin, M. Katsuyama, M. Matsuki, S. Takai, K. Yamanishi, M. Miyazaki, H. Matsubara, et al. Nox1 Is Involved in Angiotensin II-Mediated Hypertension: A Study in Nox1-Deficient Mice Circulation, October 25, 2005; 112(17): 2677 - 2685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Cheng, W. Cao, C. Fiocchi, J. Behar, P. Biancani, and K. M. Harnett Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G418 - G428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I.-S. Song, S. Tatebe, W. Dai, and M. T. Kuo Delayed Mechanism for Induction of {gamma}-Glutamylcysteine Synthetase Heavy Subunit mRNA Stability by Oxidative Stress Involving p38 Mitogen-activated Protein Kinase Signaling J. Biol. Chem., August 5, 2005; 280(31): 28230 - 28240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Szotowski, S. Antoniak, W. Poller, H.-P. Schultheiss, and U. Rauch Procoagulant Soluble Tissue Factor Is Released From Endothelial Cells in Response to Inflammatory Cytokines Circ. Res., June 24, 2005; 96(12): 1233 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Takeda, E. Suzuki, H. Satonaka, S. Oba, H. Nishimatsu, M. Omata, T. Fujita, R. Nagai, and Y. Hirata Blockade of Endogenous Cytokines Mitigates Neointimal Formation in Obese Zucker Rats Circulation, March 22, 2005; 111(11): 1398 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Petnehazy, K. Y. Stokes, J. M. Russell, and D. N. Granger Angiotensin II Type-1 Receptor Antagonism Attenuates the Inflammatory and Thrombogenic Responses to Hypercholesterolemia in Venules Hypertension, February 1, 2005; 45(2): 209 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Bongartz, M. J. Cramer, P. A. Doevendans, J. A. Joles, and B. Braam The severe cardiorenal syndrome: 'Guyton revisited' Eur. Heart J., January 1, 2005; 26(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Wisse The Inflammatory Syndrome: The Role of Adipose Tissue Cytokines in Metabolic Disorders Linked to Obesity J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2792 - 2800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Williams, J. S. Pollock, and D. M. Pollock Arterial Pressure Response to the Antioxidant Tempol and ETB Receptor Blockade in Rats on a High-Salt Diet Hypertension, November 1, 2004; 44(5): 770 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Nickenig Should Angiotensin II Receptor Blockers and Statins Be Combined? Circulation, August 24, 2004; 110(8): 1013 - 1020. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||